USR Parent Offers To Acquire ODP For $40 Per Share In Cash - Quick Facts

USR Parent, Inc. or Staples said Monday it has sent a letter to the board of directors of ODP Corp. (ODP), outlining a proposal to acquire all of the issued and outstanding common stock of ODP for $40.00 per share in cash. Shares of ODP are gaining more than 9 percent in pre-market activity.

ODP is a provider of business services, products and technology solutions for small, medium and enterprise businesses.

"Staples believes that its all-cash transaction is a compelling value proposition for ODP's stockholders that offers a high degree of certainty and is superior to the intrinsic, standalone value of ODP," Staples said in the letter.

Further, Staples said it may increase its proposed valuation for logical strategic divestitures that ODP may execute to unlock value, such as the sale of its CompuCom business, or if ODP conducts a comprehensive sale process for its U.S. commercial business unit.

Staples noted that certain of its affiliates own about 4.9 percent of ODP's common stock, and it is fully committed to completing the proposed transaction.

The company added it is prepared to cooperate with ODP and its board of directors to sign a reasonable negotiated merger agreement.

"Our intention is to commence a public, all-cash tender offer for 100% of ODP's outstanding shares of common stock in March 2021 in the event we cannot reach a negotiated agreement with ODP," Staples said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT